GSK PLC-SPON ADR

Reckitt’s board revamp, Innoviva‑Dr. Reddy antibiotic partnership, and biopharma’s dual IPO‑acquisition trend illustrate how pharma firms are reshaping governance, accelerating AMR solutions, and strengthening pipelines ahead of key patent cliffs.

Corporate governance overhaul: new independent directors, BSE/NSE migration, and secure remote e‑voting promise higher transparency, lower cost of capital, but also new compliance challenges and short‑term volatility.

GSK’s momelotinib earns orphan drug status for VEXAS syndrome, paving the way for the ATLAS trial and positioning a first‑in‑class JAK inhibitor in a market with no current therapies.

GSK’s $10.6B Nuvalent acquisition and adult RSV vaccine launch boost oncology and respiratory pipelines, diversifying revenue and mitigating patent cliffs.